Neutralizing antibodies for the prevention and treatment of COVID-19
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neutralizing antibodies for the prevention and treatment of COVID-19
Authors
Keywords
-
Journal
Cellular & Molecular Immunology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-08
DOI
10.1038/s41423-021-00752-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection
- (2021) Aleksandra Synowiec et al. CLINICAL MICROBIOLOGY REVIEWS
- Structures of SARS-CoV-2 RNA-Binding Proteins and Therapeutic Targets
- (2021) Muhammad Tahir Khan et al. INTERVIROLOGY
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
- (2021) Tyler N. Starr et al. SCIENCE
- Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
- (2021) Jiwan Ge et al. Nature Communications
- Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
- (2021) Zhiqiang Ku et al. Nature Communications
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
- (2021) Cheolmin Kim et al. Nature Communications
- SARS-CoV-2 Transmission From People Without COVID-19 Symptoms
- (2021) Michael A. Johansson et al. JAMA Network Open
- The antigenic anatomy of SARS-CoV-2 receptor binding domain
- (2021) Wanwisa Dejnirattisai et al. CELL
- Extremely potent human monoclonal antibodies from COVID-19 convalescent patients
- (2021) Emanuele Andreano et al. CELL
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
- (2021) Emma S. Winkler et al. CELL
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
- (2021) Xiaoying Shen et al. Cell Host & Microbe
- Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
- (2021) Allison J. Greaney et al. Cell Host & Microbe
- Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite
- (2021) Gabriele Cerutti et al. Cell Host & Microbe
- Bamlanivimab for treatment of COVID‐19 in solid organ transplant recipients: Early single‐center experience
- (2021) Abhay Dhand et al. CLINICAL TRANSPLANTATION
- Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library
- (2021) Yu Jung Kim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Envelope protein of SARS‐CoV‐2 increases intra‐Golgi pH and forms a cation channel that is regulated by pH
- (2021) David Cabrera‐Garcia et al. JOURNAL OF PHYSIOLOGY-LONDON
- Comparative research on nucleocapsid and spike glycoprotein as the rapid immunodetection targets of COVID-19 and establishment of immunoassay strips
- (2021) Dan Liu et al. MOLECULAR IMMUNOLOGY
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
- (2021) Rita E. Chen et al. NATURE MEDICINE
- Evolution of SARS-CoV-2 Envelope, Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week
- (2021) Paloma Troyano-Hernáez et al. Viruses-Basel
- Causes of death and comorbidities in hospitalized patients with COVID-19
- (2021) Sefer Elezkurtaj et al. Scientific Reports
- Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors
- (2021) Michael Mor et al. PLoS Pathogens
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
- (2021) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- SARS-CoV-2 Nucleocapsid Protein Targets RIG-I-Like Receptor Pathways to Inhibit the Induction of Interferon Response
- (2021) Soo Jin Oh et al. Cells
- Household Transmission of SARS-CoV-2
- (2021) Joshua P. Metlay et al. JAMA Network Open
- Identification and functional analysis of the SARS-COV-2 nucleocapsid protein
- (2021) Tianyi Gao et al. BMC MICROBIOLOGY
- Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
- (2021) Naveenchandra Suryadevara et al. CELL
- N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
- (2021) Matthew McCallum et al. CELL
- Antibody evasion by the P.1 strain of SARS-CoV-2
- (2021) Wanwisa Dejnirattisai et al. CELL
- Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
- (2021) Pengfei Wang et al. Cell Host & Microbe
- Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
- (2021) Renhong Yan et al. CELL RESEARCH
- Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19
- (2021) Patricia Anne O'Malley Clinical Nurse Specialist
- Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
- (2021) Carl Graham et al. IMMUNITY
- The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
- (2021) Bryan E. Jones et al. Science Translational Medicine
- Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
- (2021) Xing Zhu et al. PLOS BIOLOGY
- Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
- (2021) Amber Salter et al. JAMA Neurology
- Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
- (2021) Tal Noy-Porat et al. iScience
- The SARS-CoV-2 envelope (E) protein has evolved towards membrane topology robustness
- (2021) Gerard Duart et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
- (2021) Richard Copin et al. CELL
- An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
- (2021) Yafei Liu et al. CELL
- Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience
- (2021) John Paul Verderese et al. CLINICAL INFECTIOUS DISEASES
- Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities
- (2021) Myron S. Cohen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
- (2021) Meagan P. O’Brien et al. NEW ENGLAND JOURNAL OF MEDICINE
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
- (2020) Renhong Yan et al. SCIENCE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
- (2020) Ning Wang et al. Frontiers in Microbiology
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- (2020) Shuai Xia et al. CELL RESEARCH
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
- (2020) Wanbo Tai et al. Cellular & Molecular Immunology
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Structural basis of receptor recognition by SARS-CoV-2
- (2020) Jian Shang et al. NATURE
- Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
- (2020) Shibo Jiang et al. TRENDS IN IMMUNOLOGY
- Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
- (2020) Christopher O. Barnes et al. CELL
- Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia
- (2020) Stanley C Jordan et al. CLINICAL INFECTIOUS DISEASES
- Identification of an anti-SARS-CoV-2 receptor binding domain directed human monoclonal antibody from a naïve semi-synthetic library
- (2020) Hilal Ahmed Parray et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
- (2020) Lihong Liu et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
- (2020) Seth J. Zost et al. NATURE MEDICINE
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- (2020) Philip J. M. Brouwer et al. SCIENCE
- SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine
- (2020) Prabhat Pratap Singh Tomar et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach
- (2020) Ahmad Abu Turab Naqvi et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm
- (2020) Nicki Panoskaltsis et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model
- (2020) Jakob Kreye et al. CELL
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models
- (2020) Wei Li et al. CELL
- Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study
- (2020) Javier Martínez-Sanz et al. CLINICAL MICROBIOLOGY AND INFECTION
- Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2
- (2020) Shibo Jiang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
- (2020) Francesco Perrone et al. Journal of Translational Medicine
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
- (2020) Alina Baum et al. SCIENCE
- Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
- (2020) Ludovico Cantuti-Castelvetri et al. SCIENCE
- The engines of SARS-CoV-2 spread
- (2020) Elizabeth C. Lee et al. SCIENCE
- The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial
- (2020) Aoife Cotter et al. Trials
- Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein
- (2020) Nouredine Behloul et al. VIRUS RESEARCH
- A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
- (2020) Tal Noy-Porat et al. Nature Communications
- Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
- (2020) Shruti Gupta et al. JAMA Internal Medicine
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
- (2020) Olivier Hermine et al. JAMA Internal Medicine
- Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
- (2020) Carlo Salvarani et al. JAMA Internal Medicine
- Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
- (2020) Allison J. Greaney et al. Cell Host & Microbe
- The structural basis of accelerated host cell entry by SARS‐CoV‐2†
- (2020) Murat Seyran et al. FEBS Journal
- Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
- (2020) Reza Malekzadeh et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
- (2020) Alexandra Schäfer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial
- (2020) Panpan Liu et al. Trials
- SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-β Production
- (2020) Keli Chen et al. Viruses-Basel
- Risk factors and outcomes for acute respiratory failure in coronavirus disease 2019: An observational cohort study
- (2020) Paweł Piwowarczyk et al. Advances in Clinical and Experimental Medicine
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
- (2020) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
- (2020) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
- (2012) Ali M. Zaki et al. NEW ENGLAND JOURNAL OF MEDICINE
- The spike protein of SARS-CoV — a target for vaccine and therapeutic development
- (2009) Lanying Du et al. NATURE REVIEWS MICROBIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started